“We strive to support the industry with scientifically-sound, clinically-supported ingredients tested in healthy populations by using some of the most trusted methods and measures,” said Vijaya Juturu, PhD, senior scientific and clinical affairs director (global), OmniActive Health Technologies. “We chose to measure bioavailability using area under the plasma concentration curve (AUC) because it accurately represents the total amount of unchanged active compounds that reach systemic circulation. The results demonstrate the proven bioavailability of Lutemax 2020 at all three tested doses.”
For 12 weeks, 28 healthy subjects were randomly assigned to one of four groups: placebo, 6 mg L/1.26 mg Zi, 10mg L/2 Zi, or 20 mg L/4 mg Zi. Blood samples were collected at baseline and every two weeks thereafter (in a dose-dependent manner). Supplementation with Lutemax 2020 significantly increased serum AUC levels of lutein and zeaxanthin isomers. The findings also suggest that the high bioavailability of lutein and zeaxanthin isomers from Lutemax 2020 is due, in part, to this unique formula that contains all three macular carotenoids—lutein, RR-zeaxanthin and RS (meso)-zeaxanthin.
LAMA I is one of numerous studies slated to come out of OmniActive’s robust clinical program.
“If I had to give insight into what the industry is going to see this year from OmniActive, I would sum it up in one word: science,” said Abhijit Bhattacharya, president, OmniActive Health Technologies Ltd. “With a 5:1 balanced lutein:zeaxanthin isomer ratio manufactured from a vertically-integrated source, Lutemax 2020 has always been a popular and differentiated ingredient. LAMA I is one study in a series of soon-to-be-released research that further supports the uniqueness of Lutemax 2020 in the marketplace.”